290 related articles for article (PubMed ID: 21219397)
1. Treatment of systemic lupus erythematosus with epratuzumab.
Traczewski P; Rudnicka L
Br J Clin Pharmacol; 2011 Feb; 71(2):175-82. PubMed ID: 21219397
[TBL] [Abstract][Full Text] [Related]
2. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
3. Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases.
Steinfeld SD; Youinou P
Expert Opin Biol Ther; 2006 Sep; 6(9):943-9. PubMed ID: 16918261
[TBL] [Abstract][Full Text] [Related]
4. Epratuzumab for systemic lupus erythematosus.
Wallace DJ; Goldenberg DM
Lupus; 2013 Apr; 22(4):400-5. PubMed ID: 23553783
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
Rossi EA; Chang CH; Goldenberg DM
PLoS One; 2014; 9(5):e98315. PubMed ID: 24841238
[TBL] [Abstract][Full Text] [Related]
6. Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again.
Eisenberg R
Arthritis Res Ther; 2006; 8(3):108. PubMed ID: 16732895
[TBL] [Abstract][Full Text] [Related]
7. B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: comment on the editorial by St. Clair and Tedder.
Goldenberg DM; Stein R; Leonard JP; Steinfeld SD; Dörner T; Burmester GR
Arthritis Rheum; 2006 Jul; 54(7):2344; author reply 2344-5. PubMed ID: 16802381
[No Abstract] [Full Text] [Related]
8. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus.
Dörner T; Shock A; Goldenberg DM; Lipsky PE
Autoimmun Rev; 2015 Dec; 14(12):1079-86. PubMed ID: 26212727
[TBL] [Abstract][Full Text] [Related]
9. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.
Dörner T; Kaufmann J; Wegener WA; Teoh N; Goldenberg DM; Burmester GR
Arthritis Res Ther; 2006; 8(3):R74. PubMed ID: 16630358
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.
Gottenberg JE; Dörner T; Bootsma H; Devauchelle-Pensec V; Bowman SJ; Mariette X; Bartz H; Oortgiesen M; Shock A; Koetse W; Galateanu C; Bongardt S; Wegener WA; Goldenberg DM; Meno-Tetang G; Kosutic G; Gordon C
Arthritis Rheumatol; 2018 May; 70(5):763-773. PubMed ID: 29381843
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus.
Rao V; Gordon C
Immunotherapy; 2014; 6(11):1165-75. PubMed ID: 25496332
[TBL] [Abstract][Full Text] [Related]
12. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.
Rossi EA; Goldenberg DM; Michel R; Rossi DL; Wallace DJ; Chang CH
Blood; 2013 Oct; 122(17):3020-9. PubMed ID: 23821660
[TBL] [Abstract][Full Text] [Related]
13. B-cell-depleting therapy in systemic lupus erythematosus.
Ramos-Casals M; Sanz I; Bosch X; Stone JH; Khamashta MA
Am J Med; 2012 Apr; 125(4):327-36. PubMed ID: 22444096
[TBL] [Abstract][Full Text] [Related]
14. B-cell-targeted therapy for systemic lupus erythematosus: an update.
Ding C; Foote S; Jones G
BioDrugs; 2008; 22(4):239-49. PubMed ID: 18611066
[TBL] [Abstract][Full Text] [Related]
15. Epratuzumab for the treatment of systemic lupus erythematosus.
Geh D; Gordon C
Expert Rev Clin Immunol; 2018 Apr; 14(4):245-258. PubMed ID: 29542345
[TBL] [Abstract][Full Text] [Related]
16. Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study.
Tsuru T; Tanaka Y; Kishimoto M; Saito K; Yoshizawa S; Takasaki Y; Miyamura T; Niiro H; Morimoto S; Yamamoto J; Lledo-Garcia R; Shao J; Tatematsu S; Togo O; Koike T
Mod Rheumatol; 2016; 26(1):87-93. PubMed ID: 26382733
[TBL] [Abstract][Full Text] [Related]
17. Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies.
Fattah Z; Isenberg DA
Expert Opin Biol Ther; 2014 Mar; 14(3):311-26. PubMed ID: 24387632
[TBL] [Abstract][Full Text] [Related]
18. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data.
Looney RJ
Drugs; 2010 Mar; 70(5):529-40. PubMed ID: 20297867
[TBL] [Abstract][Full Text] [Related]
19. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.
Daridon C; Blassfeld D; Reiter K; Mei HE; Giesecke C; Goldenberg DM; Hansen A; Hostmann A; Frölich D; Dörner T
Arthritis Res Ther; 2010; 12(6):R204. PubMed ID: 21050432
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
